The brief reign of Novo Nordisk’s Wegovy pill as the lone oral GLP-1 approved for obesity has ended as Eli Lilly’s orforglipron cruised past an FDA green light Wednesday. Now christened Foundayo, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results